Breaking News Headlines Today

News from Arcutis Biotherapeutics

Your destination for news from Arcutis Biotherapeutics. See how Arcutis Biotherapeutics’s media bias impacts the breaking news stories of today.

We’ve discovered 12 headlines written by Arcutis Biotherapeutics during the past 3 months.

Arcutis Biotherapeutics’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Arcutis Biotherapeutics’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Arcutis Biotherapeutics

Where is Arcutis Biotherapeutics located?Arcutis Biotherapeutics's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Arcutis Biotherapeutics News

Westlake Village · Westlake Village

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - Arcutis Biotherapeutics (NASDAQ:ARQT)

Coverage: 2 sources

WESTLAKE VILLAGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast t…See the Story

First Infant Enrolled in Trial of Roflumilast Cream, 0.05% for Atopic Dermatitis in Infants

The phase 2 trial will be 4 weeks and evaluate investigational, once-daily roflumilast cream 0.05% in infants 3 months to less than 2 years of age.See the Story

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

50% Center coverage: 4 sources

BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on June 3,…See the Story

Arcutis’ Roflumilast Becomes First FDA-Approved Treatment to Receive the NPF’s Seal of Recognition

The National Psoriasis Foundation Seal of Recognition program has expanded to prescription drugs, making roflumilast the first to achieve the indication.Alexandria, VA · Alexandria See the Story

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Arcutis Biotherapeutics

WESTLAKE VILLAGE, Calif., May 29, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, taking place June 9-11, 2025. Details for the company’s participation are as follows: Fireside Chat Date: Tuesda…Westlake Village · Westlake Village Read Article

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update - Arcutis Biotherapeutics

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets and insurance changes, and excluding the non-recurring reduction in reserves for product return of $4.1 million reported in Q4 2024 Continued demand growth for ZORYVE of 10%, solidifying its position as most prescribed branded non-steroidal topica…Westlake Village · Westlake Village Read Article

News from Arcutis Biotherapeutics

News from Arcutis Biotherapeutics

Information about Arcutis Biotherapeutics

Media Bias Ratings

Factuality

Ownership

Top Arcutis Biotherapeutics News

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - Arcutis Biotherapeutics (NASDAQ:ARQT)

First Infant Enrolled in Trial of Roflumilast Cream, 0.05% for Atopic Dermatitis in Infants

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis’ Roflumilast Becomes First FDA-Approved Treatment to Receive the NPF’s Seal of Recognition

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Arcutis Biotherapeutics

Arcutis wins FDA nod for Zoryve foam for plaque psoriasis

New Guidance Aims to Improve Genital Psoriasis Treatment

Single steroid-free psoriasis foam treats both scalp and body

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update - Arcutis Biotherapeutics

Similar News Topics

Topics Most Covered by Arcutis Biotherapeutics

Sources Covering Similar Topics

Breaking News Topics Related to Arcutis Biotherapeutics

Information about Arcutis Biotherapeutics

Media Bias Ratings

Factuality

Ownership

First Infant Enrolled in Trial of Roflumilast Cream, 0.05% for Atopic Dermatitis in Infants

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis’ Roflumilast Becomes First FDA-Approved Treatment to Receive the NPF’s Seal of Recognition

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Arcutis Biotherapeutics

Arcutis wins FDA nod for Zoryve foam for plaque psoriasis

New Guidance Aims to Improve Genital Psoriasis Treatment

Single steroid-free psoriasis foam treats both scalp and body

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update - Arcutis Biotherapeutics